Bristol Myers Squibb Halts Clinical Development of Prothena’s PRX019

By Public Technologies20:14 (UTC), 29 October 2026 Updated

Bristol Myers Squibb notified Prothena on October 28, 2026, it would stop clinical development of PRX019 following a strategic review.
The license, signed in May 2024 with an $80 million upfront payment, will terminate on January 28, 2027.
Termination eliminates eligibility for up to $617.5 million in development, regulatory and sales milestones, as well as tiered royalties.
Previously reported Phase 1 results from the first half of 2026 showed favorable safety and tolerability, meeting prespecified biological-response targets.
Bristol Myers Squibb continues moponetug’s Phase 2 Alzheimer’s trial, with up to $562.5 million in regulatory and sales milestones remaining available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001559053-26-000026), on October 29, 2026, and is solely responsible for the information contained therein.